Abstract 422P
Background
Despite previous research highlighting treatment delay inequities in early-stage breast cancer specifically in historically marginalized groups, there is limited research on disparities in Metastatic Breast Cancer (MBC) treatment delays. This study explores treatment delay disparities in MBC treatment initiation aiming to identify contributing factors crucial for improving timely access to care for all.
Methods
Nationwide Flatiron Health electronic health records-derived deidentified database, including females aged 18+ diagnosed with MBC in the U.S. between 2011 and 2022. Treatment delay, defined as a binary variable (1 for delays >60 days between diagnosis and first-line treatment), was assessed. Statistical tests (t-tests and chi-squared) were used to analyze patient characteristics (age, race, health insurance, stage at diagnosis, site of metastasis, phenotypes, etc.) among groups with and without treatment delays. Logistic regression was employed to evaluate the association between clinical and non-clinical factors and treatment delays.
Results
Among 20,617 patients with MBC, nearly 28% had treatment delays. Patients with treatment delays were younger, uninsured, historically marginalized patients, and newly diagnosed as compared to patients without treatment delays. Logistic regression revealed higher age was associated with lower odds of treatment delays (2%, p=0.01). Patients without health insurance coverage had higher delay odds (OR: 3.16 p=0.001) as compared with those with commercial health insurance. Historically marginalized patients showed a higher likelihood of delays, ranging from 6% for Black patients to 38% for Hispanic patients (p=0.03) compared to White patients.
Conclusions
Our study highlights concerning disparities in MBC treatment delays. Patients from historically marginalized groups, and those without health insurance coverage are more likely to experience delays in MBC treatment initiation. Identifying and addressing these disparities is essential to ensure equitable healthcare and enhance overall outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
American Cancer Society.
Disclosure
G. Kimmick: Financial Interests, Advisory Board, 5/31/2018: Eisai ; Financial Interests, Advisory Board, 3/22/2018-3/23/2018: Boehringer Ingelheim 2018 ; Financial Interests, Advisory Board, 10/1/2020: Immunomedics; Financial Interests, Advisory Board, 3/23/2021: Biotheranostics; Financial Interests, Advisory Board, 7/12/2023: Novartis; Other, Personal, Advisory Role, 2019: Genomic Health 2019, Agendia; Other, Personal, Speaker’s Bureau, Interview with Niel Love 11/19/2021: Research-to-Practice; Financial Interests, Royalties: UpToDate, Springer; Other, Personal and Institutional, Research Funding: Abbott Laboratories, AbbVie, Abraxis BioScience, Alphavax, AstraZeneca, Bionovo, BiPar Sciences, Bristol Meyers Squibb, Celldex Therapeutics, Celsion, EMD Serono, Exelixis, Genentech, GSK (CARG Trial), Incyte Corporation. All other authors have declared no conflicts of interest.
Resources from the same session
523P - A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)
Presenter: Munehiro Wakabayashi
Session: Poster session 15
524P - A phase II study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with metastatic colorectal cancer who failed two prior standard chemotherapies
Presenter: Ahreum Lim
Session: Poster session 15
525P - Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody
Presenter: Keiji Sugiyama
Session: Poster session 15
526P - Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age
Presenter: Maria Elena Elez Fernandez
Session: Poster session 15
527P - Effect of trifluridine/tipiracil (FTD/TPI) in combination with bevacizumab (bev) in patients treated in SUNLIGHT by clinical prognostic factors at baseline
Presenter: Josep Tabernero
Session: Poster session 15
529P - Evaluating metastatic disease sites as a prognostic marker in patients receiving sequential treatment with regorafenib and trifluridine/tipiracil for refractory colorectal cancer: Survival outcomes from the multicenter retrospective “ReTrITA” study
Presenter: Carlo Signorelli
Session: Poster session 15
530P - Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
Presenter: Andreas Seeber
Session: Poster session 15
531P - Prognostic value of liver metastases, KRAS mutations and race in colorectal cancer patients: A pooled analysis of third-line placebo-controlled trials from the ARCAD database
Presenter: Thierry André
Session: Poster session 15
532P - G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study
Presenter: Jean-Baptiste Bachet
Session: Poster session 15